PRNewsWire
15 Nov 2026, 20:00 UTC · 1d ago
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
Impact · against what's priced in
IDEAYA expands its long-term pipeline valuation by nominating IDE101, a first-in-class candidate for CDKN2A-deficient solid tumors. While the clinical catalyst is distant (IND filing H1 2027), the asset adds a new vertical for the company's precision medicine platform beyond its existing PRMT5 programs.
- IDYA+0.60
No priced-in read yet





